Kevin Conroy is the Chief Executive Officer, President, and Chairman of the Board of Exact Sciences. He became CEO 11 years ago and he has been part of a team that transformed Exact Sciences into one of the world's premier cancer diagnostics companies with more than 4,500 employees. Mr. Conroy has led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its noninvasive colorectal cancer screening test, Cologuard. This culminated with Cologuard becoming the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States. In 2019, Exact Sciences' acquisition of Genomic Health, Inc., united two of the industry's strongest brands, Cologuard and Oncotype DX, and established the company's position as the global leader in advanced cancer diagnostics. Before joining Exact Sciences, Mr. Conroy served as CEO and President of Third Wave Technologies, a molecular diagnostics company that developed a breakthrough cervical cancer screening test before being acquired by Hologic in 2008. Mr. Conroy holds a Bachelor of Science degree in electrical engineering from Michigan State University and earned his Juris Doctorate from the University of Michigan Law School.